Nusano is supplying the fight against cancer by making medical radioisotopes available and abundant
Nusano is a privately held physics company committed to bringing stability and innovation to the rapidly emerging and critically undersupplied medical radioisotopes market. The company plans to deliver commercial volumes of lutetium-177 in Q1 2025, followed by actinium-225 in Q3 2025. These programs will be supported and enabled by Nusano’s state-of-the-art radioisotope production facility in West Valley City, Utah, and proprietary reactor-based separation technology.
Nusano's ion source is smaller and more efficient than existing production methods. This results in significantly greater yields and allows for the simultaneous manufacturing of multiple radioisotopes. The Nusano platform will be capable of generating more than 25 radioisotopes of interest to medicine, and the simultaneous production of up to 12 different radioisotopes. The result is one of the first significant advancements in radioisotope production in decades – a multifaceted platform capable of producing both the variety and volume of isotopes needed to enable new therapeutics.
For more, please visit www.nusano.com.